Last reviewed · How we verify
AFOLIA
AFOLIA is a folate receptor alpha (FRα) antagonist designed to modulate immune responses and enhance fertility outcomes.
AFOLIA is a folate receptor alpha (FRα) antagonist designed to modulate immune responses and enhance fertility outcomes. Used for Infertility or subfertility (indication under Phase 3 investigation).
At a glance
| Generic name | AFOLIA |
|---|---|
| Also known as | Follitropin-alfa, Follitropin Alfa |
| Sponsor | Fertility Biotech AG |
| Target | Folate receptor alpha (FRα) |
| Modality | Small molecule |
| Therapeutic area | Fertility / Reproductive Health |
| Phase | Phase 3 |
Mechanism of action
The drug targets folate receptor alpha, which is expressed on immune cells and reproductive tissues. By modulating FRα signaling, AFOLIA aims to improve reproductive function and fertility outcomes. The exact immunological or reproductive mechanism in Phase 3 development remains proprietary to Fertility Biotech AG.
Approved indications
- Infertility or subfertility (indication under Phase 3 investigation)
Common side effects
Key clinical trials
- Comparative Pharmacokinetics of AFOLIA and US Gonal-f® RFF Redi-ject After Single Subcutaneous Application (PHASE1)
- Phase III Study Comparing Efficacy and Safety of AFOLIA vs Gonal-f® RFF in Women (35 to 42) Undergoing IVF (PHASE3)
- Multi-centre Study to Compare Efficacy and Safety of AFOLIA and Gonal-f in Women for Assisted Reproductive Treatment (PHASE3)
- Comparative Pharmacokinetics of AFOLIA and Gonal-f® After Single Subcutaneous Application (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |